# A Study to Test How Well BI 1291583 is Tolerated by People With Cystic Fibrosis Bronchiectasis (Clairafly™)

> **NCT05865886** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 22 (actual)

## Conditions studied

- Cystic Fibrosis
- Bronchiectasis

## Interventions

- **DRUG:** BI 1291583
- **DRUG:** Placebo to BI 1291583

## Key facts

- **NCT ID:** NCT05865886
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-04-05
- **Primary completion:** 2024-10-07
- **Final completion:** 2024-10-07
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2025-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05865886

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05865886, "A Study to Test How Well BI 1291583 is Tolerated by People With Cystic Fibrosis Bronchiectasis (Clairafly™)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05865886. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*